{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-036510","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2022-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.807629+00:00","generated_at":"2026-06-20T23:40:50.816698+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ZyVersa extends waiver of $1.5M milestone payments due to L&F Research to March 31, 2023","bullets":["Second Amendment to Waiver extends L&F Research's forbearance on terminating license for non-payment of $500K IND Milestone and two $500K Phase 1/2 milestone payments.","Waiver Period extended to March 31, 2023; original deadline was January 3, 2023.","If license is terminated for other reasons or a bankruptcy event occurs before July 31, 2023, the waiver is void and payment obligations retroactively reinstated.","All other terms of the underlying License Agreement remain unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-036510","json":"https://secwatch.observer/filing/0001493152-22-036510.json","markdown":"https://secwatch.observer/filing/0001493152-22-036510.md","text":"https://secwatch.observer/filing/0001493152-22-036510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222036510/0001493152-22-036510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222036510/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T23:40:50.816698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7734f78dd873f33cde4ae30701205e17c4f04eb2","claim":"ZyVersa Therapeutics, Inc. amended Second Amendment to Waiver of Certain Rights under License Agreement with L&F Research LLC valued at $1,500,000 (effective 2022-12-23).","evidence_excerpt":"On December 23, 2022, ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”) entered into a Second Amendment to Waiver of Certain Rights under License Agreement, by and between L&F Research and ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”), a wholly owned subsidiary of the Company (the “Second Amendment”), amending the previously disclosed Waiver Agreement, dated March 2, 2022, by and between L&F Research and Old ZyVersa (the “Waiver Agreement”), as amended.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315222036510/0001493152-22-036510-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"L&F Research LLC"},{"label":"Value","value":"$1,500,000"},{"label":"Effective","value":"2022-12-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}